Prevalence of Neutralizing Antibodies against Adenoviruses types -C5, -D26 and -B35 used in vaccination platforms, in Healthy and HIV-Infected Adults and Children from Burkina Faso and Chad

Aline Raissa Ouoba, Océane Paris, Chatté Adawaye, Guy Takoudjou Dzomo, Abderrazzack Adoum Fouda, Dramane Kania, Amidou Diarra, Zenaba Abdramane Kallo, Isidore Tiandiogo Traore, Sodiomon Bienvenu Sirima, Edouard Tuaillon, Philippe Van de Perre, Eric J. Kremer, Franck Jean Daniel Mennechet
doi: https://doi.org/10.1101/2022.06.07.22276076

Data Availability

All data produced in the present study are available upon reasonable request to the authors. All data produced in the present work are contained in the manuscript.

Back to top
Posted June 07, 2022.
Download PDF
Data/Code
Email
Prevalence of Neutralizing Antibodies against Adenoviruses types -C5, -D26 and -B35 used in vaccination platforms, in Healthy and HIV-Infected Adults and Children from Burkina Faso and Chad
Aline Raissa Ouoba, Océane Paris, Chatté Adawaye, Guy Takoudjou Dzomo, Abderrazzack Adoum Fouda, Dramane Kania, Amidou Diarra, Zenaba Abdramane Kallo, Isidore Tiandiogo Traore, Sodiomon Bienvenu Sirima, Edouard Tuaillon, Philippe Van de Perre, Eric J. Kremer, Franck Jean Daniel Mennechet
medRxiv 2022.06.07.22276076; doi: https://doi.org/10.1101/2022.06.07.22276076
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area